Dendritic cellsa
|
Tumor gradeb
|
---|
|
Grade I
|
Grade II
|
Grade III
|
---|
CD83-expressing cells
| | | |
Tumor-free SLNs
| | | |
Number
|
3
|
11
|
8
|
Mean (± SEM)
|
4.5 ± 4.5
|
10.2 ± 3.5
|
13.0 ± 2.9
|
Median
|
0
|
8
|
16.7
|
Range
|
0–13.4
|
0.4–38.4
|
0.4–21.8
|
Tumor-containing SLNs
| | | |
Number
|
3
|
12
|
8
|
Mean (± SEM)
|
9.1 ± 2.7
|
4.9 ± 1.3
|
5.8 ± 1.8
|
Median
|
9.2
|
3.3
|
5.5
|
Range
|
4.4–13.6
|
0–14.2
|
0.6–15.4
|
P valuec
|
0.40
|
0.34
|
0.16
|
CD1a-expressing cells
| | | |
Tumor-free SLNs
| | | |
Number
|
3
|
11
|
8
|
Mean (± SEM)
|
57.9 ± 5.6
|
60.0 ± 10.5
|
49.0 ± 5.1
|
Median
|
63.2
|
63.5
|
48.6
|
Range
|
46.8–63.8
|
0–97.0
|
25.6–70.6
|
Tumor-containing SLNs
| | | |
Number
|
3
|
12
|
8
|
Mean (± SEM)
|
59.0 ± 23.5
|
48.7 ± 8.5
|
80.0 ± 8.1
|
Median
|
53.2
|
41.6
|
74.3
|
Range
|
21.6–102.2
|
12.4–102.0
|
54.4–122.8
|
P value
|
1.0
|
0.41
|
0.01
|
- SEM, standard error of the mean. a Number of cells per high-powered field. b The grade was unknown for two tumors in the tumor-containing SLN group and for three tumors in the tumor-free SLN group. c P values determined by the Wilcoxon rank sum test comparing the number of CD83-expressing or CD1a-expressing dendritic cells in tumor-free SLNs versus tumor-containing SLNs for each tumor grade.